PLRX

$0.00

(

+0.00%

)
Quote details

stock

Pliant Therapeutics Inc

NASDAQ | PLRX

1.52

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$88.40M

Market Cap

-

P/E Ratio

-3.38

EPS

$16.10

52 Week High

$1.10

52 Week Low

HEALTHCARE

Sector

PLRX Chart

Recent Chart
Price Action

PLRX Technicals

Tags:

PLRX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$2.1M
Total Revenue $0
Cost Of Revenue $2.1M
Costof Goods And Services Sold $2.1M
Operating Income -$228M
Selling General And Administrative $59M
Research And Development $169M
Operating Expenses $228M
Investment Income Net -
Net Interest Income $18M
Interest Income $21M
Interest Expense $3M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$39M
Income Before Tax -$210M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$210M
Comprehensive Income Net Of Tax -
Ebit -$189M
Ebitda -$228M
Net Income -$210M

Revenue & Profitability

Earnings Performance

PLRX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $397M
Total Current Assets $362M
Cash And Cash Equivalents At Carrying Value $71M
Cash And Short Term Investments $71M
Inventory -
Current Net Receivables $2.3M
Total Non Current Assets $35M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $285M
Other Current Assets $4.2M
Other Non Current Assets -
Total Liabilities $93M
Total Current Liabilities $33M
Current Accounts Payable $6M
Deferred Revenue -
Current Debt -
Short Term Debt $542K
Total Non Current Liabilities $60M
Capital Lease Obligations $30M
Long Term Debt $30M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $60M
Other Current Liabilities $27M
Other Non Current Liabilities -
Total Shareholder Equity $304M
Treasury Stock -
Retained Earnings -$710M
Common Stock $6K
Common Stock Shares Outstanding $61M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$156M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.1M
Capital Expenditures $3.8M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $140M
Cashflow From Financing $23M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$210M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$2.1M
Total Revenue $0
Cost Of Revenue $2.1M
Costof Goods And Services Sold $2.1M
Operating Income -$228M
Selling General And Administrative $59M
Research And Development $169M
Operating Expenses $228M
Investment Income Net -
Net Interest Income $18M
Interest Income $21M
Interest Expense $3M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$39M
Income Before Tax -$210M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$210M
Comprehensive Income Net Of Tax -
Ebit -$189M
Ebitda -$228M
Net Income -$210M

PLRX News

PLRX Profile

Pliant Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Pliant Therapeutics, Inc., headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrosis and related diseases. With a robust pipeline targeting conditions such as idiopathic pulmonary fibrosis and other fibrotic diseases, Pliant aims to address significant unmet medical needs through innovative treatments. The company's expertise in fibroblast biology and small molecule drug development positions it uniquely within the rapidly evolving biopharmaceutical landscape.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
YAAS
-31.07%
$0.06
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
WOK
-5.22%
$0.08
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
ETHD
-6.19%
$3.94
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
SHOT
+12.24%
$0.28
RR
+2.68%
$4.20
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
YAAS
-31.07%
$0.06
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
SNAP
-0.72%
$8.27
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
WOK
-5.22%
$0.08
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
ETHD
-6.19%
$3.94
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
SHOT
+12.24%
$0.28
RR
+2.68%
$4.20
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RIVN
-0.95%
$15.59
ONDS
-1.16%
$7.66
SOFI
-0.49%
$27.98
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.